Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2297-2303

  Ren, Pengfei ^a,b   Ye, Hua ^a,b   Dai, Liping ^b   Liu, Mei ^b   Liu, Xinxin ^b   Chai, Yurong ^b   Shao, Qing ^b   Li, Yang ^b   Lei, Ningjing ^b   Peng, Bo ^b   Yao, Wu ^b   Zhang, Jianying ^a,b  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

Autoantibody; Biomarker; Esophageal squamous cell carcinoma; Immunodiagnosis; Peroxiredoxin 1

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; PEROXIREDOXIN 1; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SCREENING; ANTIBODY TITER; ANTIGEN FUNCTION; ARTICLE; AUTOIMMUNITY; BLOOD ANALYSIS; CANCER CELL CULTURE; CANCER TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TISSUE MICROARRAY;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN PEROXIDE; PEROXIREDOXINS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84885077025     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2714     Document Type: Article

References (31)

1. Lee SY and Jeoung D: The reverse proteomics for identification of tumor antigens. J Microbiol Biotechnol 17: 879-890, 2007.
2. Fernández Madrid F, Tang N, Alansari H, Karvonen RL and Tomkiel JE: Improved approach to identify cancer-associated autoantigens. Autoimmun Rev 4: 230-235, 2005.
3. Rhee SG: Cell signaling. H2O2, a necessary evil for cell signaling. Science 312: 1882-1883, 2006.
4. Rhee SG, Chae HZ and Kim K: Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
5. Neumann CA, Cao J and Manevich Y: Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 8: 4072-4078, 2009.
6. Cao J, Schulte J, Knight A, et al: Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 28: 1505-1517, 2009.
7. Hoshino I, Matsubara H, Akutsu Y, et al: Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep 18: 867-871, 2007.
8. Zhang J, Wang K, Zhang J, Liu SS, Dai L and Zhang JY: Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 10: 2863-2872, 2011.
9. Kim YJ, Lee WS, Ip C, Chae HZ, Park EM and Park YM: Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res 66: 7136-7142, 2006.
10. Kim JH, Bogner PN, Baek SH, et al: Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res 14: 2326-2333, 2008.
11. Chang JW, Lee SH, Jeong JY, et al: Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 579: 2873-2877, 2005.
12. Yonglitthipagon P, Pairojkul C, Chamgramol Y, et al: Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol 43: 1719-1730, 2012.
13. Li J, Yang ZL, Ren X, et al: ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol 34: 359-368, 2013.
14. Quan C, Cha EJ, Lee HL, Han KH, Lee KM and Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 175: 1512-1516, 2006.
15. Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA and Gollnick SO: Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res 71: 1637-1646, 2011.
16. Chung KH, Lee DH, Kim Y, et al: Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res 9: 451-457, 2010.
17. Gordis L: Assessing the validity and reliability of diagnostic and screening tests. Epidemiology 3: 71-94, 1996.
18. Das S, Otani H, Maulik N and Das DK: Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling. J Mol Cell Cardiol 41: 248-255, 2006.
19. Kamata H, Honda S, Maeda S, Chang L, Hirata H and Karin M: Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661, 2005.
20. Wen ST and Van Etten RA: The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11: 2456-2467, 1997.
21. Neumann CA, Krause DS, Carman CV, et al: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565, 2003.
22. Benhar M, Dalyot I, Engelberg D and Levitzki A: Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 21: 6913-6926, 2001.
23. Barranco-Medina S, Lázaro JJ and Dietz KJ: The oligomeric conformation of peroxiredoxins links redox state to function. FEBS Lett 583: 1809-1816, 2009.
24. Sirvent A, Benistant C and Roche S: Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 100: 617-631, 2008.
25. Mu ZM, Yin XY and Prochownik EV: Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 277: 43175-43184, 2002.
26. Hoskins ER, Hood BL, Sun M, Krivak TC, Edwards RP and Conrads TP: Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One 6: e25056, 2011.
27. Hoshino I, Matsubara H, Hanari N, et al: Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 11: 7945-7952, 2005.
28. Chen MF, Keng PC, Shau H, et al: Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 64: 581-591, 2006.
29. Liu H, Zhang J, Wang S, et al: Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol 36: 82-88, 2012.
30. Backes C, Ludwig N, Leidinger P, et al: Immunogenicity of autoantigens. BMC Genomics 12: 340, 2011.
31. Tan EM and Zhang J: Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 222: 328-340, 2008.